Introduction
============

COPD is a slowly progressive disorder characterized by partially reversible chronic airway obstruction.[@b1-copd-12-2465],[@b2-copd-12-2465] Besides its lung manifestation, COPD has been considered to be a systemic disease in recent years due to its significant extrapulmonary findings.[@b3-copd-12-2465] The body mass index (BMI), which can indirectly represent the degree of obesity, is one of the variables that affects the phenotypic expression of the disease, its course, and prognosis.[@b3-copd-12-2465]--[@b9-copd-12-2465] Use of the BMI is recommended by the National Heart Lung and Blood Institute (NHLBI)[@b10-copd-12-2465] and it has been shown to contribute toward the expression of COPD phenotypes.[@b11-copd-12-2465],[@b12-copd-12-2465] BMI is included in the Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise (BODE) index, which predicts the prognosis of patients with COPD.[@b3-copd-12-2465] A low BMI is associated with increased mortality in patients with COPD[@b3-copd-12-2465],[@b10-copd-12-2465],[@b13-copd-12-2465] through its influences on pulmonary mechanics,[@b14-copd-12-2465] diaphragmatic muscle weakness,[@b15-copd-12-2465] decreased lung function,[@b16-copd-12-2465] as well as systemic inflammation and its biomarkers.[@b17-copd-12-2465],[@b18-copd-12-2465] Furthermore, a low body weight is associated with low health-related quality of life.[@b19-copd-12-2465]--[@b21-copd-12-2465]

With the increasing prevalence of obesity in Asia, BMI as a disease predictor has increased in importance. However, there has been controversy when applying international criteria for obesity to an Asian population, and there have been attempts to reinterpret the BMI cutoffs for Asian and Pacific populations.[@b22-copd-12-2465],[@b23-copd-12-2465] The World Health Organization (WHO) expert consultation identified further potential public health action points (23.0, 27.5, 32.5, and 37.5 kg/m^2^).[@b24-copd-12-2465] In Asia-Pacific countries including Korea, the agreed cutoff for inclusion in the overweight category is 23.0 kg/m^2^.[@b25-copd-12-2465] Asian populations have a higher risk of developing comorbidities such as cardiovascular disease and type 2 diabetes at BMIs lower than 25 kg/m^2^, which is the WHO cutoff point for overweight and, in addition, association between BMI and body fat percentage is different from that for Europeans.[@b24-copd-12-2465] The prevalence of metabolically obese but normal-weight patients in Korea is almost twice that found in the United States (US) population[@b26-copd-12-2465] and, compared to the non-Asian population, their muscle mass is smaller.

Very few studies have evaluated the correlation between BMI and the disease severity of patients with COPD according to the degree of obesity in Asians. We hypothesized that patients with COPD in different BMI groups would exhibit different manifestations of COPD and proportions of comorbidities. In addition, applying two BMI classifications and comparing the related clinical variables can be clinically significant and, to our knowledge, no study comparing two BMI classification systems has been reported.

Our study compared the clinical characteristics, disease severity, and COPD-related comorbidities of Korean patients with COPD in different BMI categories based on both the WHO and Asia-Pacific BMI classifications.

Patients and methods
====================

Study participants
------------------

Patients registered in the Korean COPD Subtype Study (KOCOSS) were recruited from 48 tertiary referral hospitals in Korea and were required to visit the hospital to update their COPD status by self-administered questionnaires at least every 6 months.[@b27-copd-12-2465] The inclusion criteria were as follows: age ≥40 years and post-bronchodilator forced expiratory volume in 1 second (FEV~1~)/forced vital capacity (FVC) \<0.7. The medical history taken from patient questionnaires as well as measurements from their initial visit were used as baseline data. Age, sex, St George's Respiratory Questionnaire (SGRQ-C) response, and the modified Medical Research Council (mMRC) dyspnea scale score of patients were recorded. Post-bronchodilator FEV~1~, FVC, and FEV~1~/FVC were checked by pulmonary function tests. Six-minute walk tests (6MWT) were also performed at the time of enrollment.

BMI and categorization
----------------------

According to the NHLBI,[@b10-copd-12-2465] BMI is calculated as weight in kilograms divided by the square of the height in meters (kg/m^2^) and is categorized into four groups according to the Asian-Pacific cutoff points ([Table 1](#t1-copd-12-2465){ref-type="table"}):[@b25-copd-12-2465] underweight (\<18.5 kg/m^2^), normal weight (18.5--22.9 kg/m^2^), overweight (23--24.9 kg/m^2^), and obese (≥25 kg/m^2^). For comparison, BMI was also categorized into four groups according to the conventional WHO classification:[@b10-copd-12-2465] underweight (\<18.5 kg/m^2^), normal weight (18.5--24.9 kg/m^2^), overweight (25--29.9 kg/m^2^), and obese (≥30 kg/m^2^).

Ethnic backgrounds
------------------

Among Korean nationals, 96% are of Korean origin and most immigrants have an Asian background (People's Republic of China, Vietnam, Japan, etc).[@b28-copd-12-2465] All patients in this cohort were citizens of the Republic of Korea.

Comorbidities
-------------

At the time of enrollment to the cohort, patient comorbidities were checked. History of myocardial infarction, heart failure, peripheral vessel disease, diabetes mellitus, hypertension, osteoporosis, gastroesophageal reflux disease, dyslipidemia, thyroid disorder, inflammatory bowel disease, bronchiectasis, previously diagnosed COPD, measles, pertussis, pneumonia, asthma, allergic rhinitis, and atopic dermatitis were carefully evaluated.

Ethics statement
----------------

For KOCOSS patients, written informed consent was obtained from all study participants. Ethics approval for the KOCOSS cohort was obtained from the ethics committee at each center. We also received approval from each center to use clinical records of their subjects for the study while maintaining patient confidentiality with regard to the data. The official name of each approving ethics committee is listed in the Supplementary materials.

Statistical analysis
--------------------

Continuous variables are reported as mean ± standard deviation. When comparing clinical parameters between BMI groups, an analysis of variance (ANOVA) test was performed for continuous variables, while the chi-squared test was performed for categorical variables. Pearson's coefficient comparison was used to determine linear associations between numerical variables. Statistical significance was established at a *P*-value \<0.05. The Mantel--Haenszel chi-squared test was performed to determine the association between categorical variables.

Results
=======

Clinical characteristics
------------------------

[Table 2](#t2-copd-12-2465){ref-type="table"} lists the baseline characteristics of the study participants. The study included 1,462 subjects, and the number of male patients was 1,396 (90.8%). The mean patient age was 70.5±7.8 years. The predicted mean post-bronchodilator FEV~1~ percentage was 55.6%±18.3%. The mean FVC was 80.5±17.5 and FEV~1~/FVC was 48.8±12.3. The mean BMI was 22.8±3.4 kg/m^2^. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage II was seen in the greatest proportion of this COPD cohort, with 758 (52.0%) patients falling into this category. The mean SGRQ-C was 34.6±19.0 and the mean COPD assessment test score was 15.8±7.8. The mean mMRC score was 1.5±0.9.

Distribution of BMI
-------------------

[Figures 1](#f1-copd-12-2465){ref-type="fig"} and [2](#f2-copd-12-2465){ref-type="fig"} present the distribution of BMI values among study subjects. The mean BMI value was 22.8 \[95% confidence interval (CI) 22.6--23.0\] and the median value was 22.7. The lowest BMI value was 13.50, whereas the highest was 35.99 ([Figure 1](#f1-copd-12-2465){ref-type="fig"}). [Figure 2](#f2-copd-12-2465){ref-type="fig"} shows the distribution of BMI values among the entire study population.

Correlation of major variables with different BMI categories
------------------------------------------------------------

The SGRQ-C was found to be in a linearly decreasing relationship with BMI (Pearson coefficient of correlation r=−0.14, *P*\<0.01). However, the post-bronchodilator FEV~1~ was in a linearly increasing relationship with BMI (r=0.21, *P*\<0.01). The diffusing capacity of the lung for carbon monoxide (DLCO) percentage and DLCO/alveolar volume (VA) were also in a linearly increasing relationship with BMI (r=0.22, *P*\<0.01 and r=0.41, *P*\<0.01, respectively; [Figure 3](#f3-copd-12-2465){ref-type="fig"}).

Furthermore, we evaluated differences in the values of major variables when the BMI groups changed ([Table 3](#t3-copd-12-2465){ref-type="table"}). Changes in variables were also evaluated according to each classification system (WHO and Asia-Pacific). No significant change in the mean age was observed in either classification. A comparison of the normal weight group to the overweight group revealed that the proportion of male patients decreased gradually. Between the underweight and normal weight groups, SGRQ-C and mMRC scores were in a decreasing relationship in both the WHO and Asia-Pacific classifications. However, the two variables increased from the overweight to the obese group.

When the WHO cutoffs were applied, an inverse "U"-shaped pattern was observed for FEV~1~. When the Asia-Pacific cutoffs were applied, FEV~1~ was in a linearly ascending relationship, whereas DLCO (%) was in a linearly increasing relationship with BMI when the Asia-Pacific cutoffs were applied. However, DLCO (%) had an inverse "U"-shaped pattern when the WHO cutoffs were applied ([Table 3](#t3-copd-12-2465){ref-type="table"}).

FEV~1~ (%) and BMI categories
-----------------------------

We compared the mean BMI of the groups of patients classified according to the GOLD criteria ([Figure 4](#f4-copd-12-2465){ref-type="fig"}) and found that mean BMI decreases as the severity of airway obstruction increases. Mean BMI was 23.6 kg/m^2^ in the GOLD 1 group and 21.2 kg/m^2^ in the GOLD 4 group. [Figure 5](#f5-copd-12-2465){ref-type="fig"} shows the proportion of each BMI group. [Figure 5A](#f5-copd-12-2465){ref-type="fig"} shows the proportion of each BMI group according to the WHO cutoffs, and [Figure 5B](#f5-copd-12-2465){ref-type="fig"} shows proportions according to the Asia-Pacific cutoffs. When WHO cutoffs were applied, 2.4% of the patients fell into the obese category, while 25.5% of the patients were found to be obese according to the Asia-Pacific cutoffs.

[Table 4](#t4-copd-12-2465){ref-type="table"} shows the proportion of each BMI group according to the GOLD criteria. As the severity of the GOLD criteria increases, proportions of the different BMI categories by both WHO and Asia-Pacific cutoffs change with statistical significance (*P*-value \<0.001). However, when WHO cutoffs were applied, the percentage of the obese group decreased after an initial increase. Conversely, when the Asia-Pacific cutoffs were applied, the percentage in the obese group linearly decreased as the GOLD criteria increased in severity. The percentage in the underweight patient group increased from 5.5% to 21.4% as the GOLD criteria changed from 1 to 4 for both BMI classifications.

Comorbidities
-------------

Comorbidities were observed in different percentages in different BMI categories. [Figure 6A](#f6-copd-12-2465){ref-type="fig"} presents the comorbidities of patients in different BMI groups classified according to the WHO cutoffs, while [Figure 6B](#f6-copd-12-2465){ref-type="fig"} presents those in BMI groups according to the Asia-Pacific cutoffs. Both graphs show that the percentage of patients with hypertension, diabetes, and hyperlipidemia increased as the groups became more obese. The percentage of patients with congestive heart failure, myocardial infarction, and peripheral vascular disease was also highest in the obese groups. Osteoporosis had the highest proportion of patients in the obese group when the WHO classification was applied and also had the highest proportion of patients in the underweight group when the Asia-Pacific classification was applied ([Figure 6](#f6-copd-12-2465){ref-type="fig"}).

Discussion
==========

The present COPD cohort study evaluated COPD manifestation and comorbidity in different BMI categories. First, FEV~1~ worsened as the BMI groups changed from obese to underweight. Second, the quality of life and dyspnea score improved as the BMI groups changed from underweight to overweight. Third, comorbidities were observed in different proportions according to the BMI group. Two BMI classifications were used to assess the clinical correlation between clinical parameters and BMI, and several differences were observed.

These results reveal that a low BMI is associated with worse health-related quality of life in patients with COPD, and this result is consistent with those of previous studies.[@b19-copd-12-2465]--[@b21-copd-12-2465],[@b29-copd-12-2465] The study by Divo et al shows that the dyspnea score and SGRQ-C showed a "U" shape as the BMI category changed from underweight to obese.[@b30-copd-12-2465] In the present study, SGRQ-C and mMRC scores were lowest for the overweight group and increased in the obese group, similar to the result from a previous study.[@b30-copd-12-2465] We speculate that SGRQ-C and mMRC were worse for obese patients compared to overweight patients, due to the influence of obesity on the activities of patients with COPD. An increase in fat mass is likely to be associated with functional limitation.[@b31-copd-12-2465] Metabolic comorbidity associated with obesity may also be a contributing factor to the relative worsening of quality of life of these patients.

Post-bronchodilator FEV~1~ decreased as the patients' BMI decreased. Previous studies have reported that BMI is correlated with the severity of emphysema, with low-BMI COPD patients more likely to have this condition;[@b30-copd-12-2465],[@b32-copd-12-2465],[@b33-copd-12-2465] such findings can provide an explanation for the linear decrease of FEV~1~ in the low-BMI group. In addition to previously reported results, the DLCO percentage gradually increased as patients were classified into groups of increasing obesity. Such a correlation between DLCO and obesity is controversial. Some studies have reported increased DLCO in more obese patients,[@b30-copd-12-2465],[@b34-copd-12-2465]--[@b36-copd-12-2465] while other studies have observed unchanged or reduced DLCO in obese patients.[@b37-copd-12-2465]--[@b39-copd-12-2465] Nevertheless, a linear decrease of DLCO in lower BMI groups should be interpreted as a correlation between emphysema and low body mass, as previous studies showing a correlation between DLCO and emphysema suggest.[@b40-copd-12-2465],[@b41-copd-12-2465] Clinical relationships of FEV~1~ and DLCO to BMI also support the previously mentioned "obesity paradox" in which patients with COPD with higher BMI have better prognosis compared to low BMI groups.[@b42-copd-12-2465],[@b43-copd-12-2465]

In this study, the WHO and Asia-Pacific BMI classifications were simultaneously applied to assess patients with COPD, and major clinical variables were evaluated for each classification system. To our knowledge, no study comparing two BMI classifications in Asian patients with COPD has previously been reported. Both BMI classification systems revealed similar changes in major variables as the patients became more obese ([Table 3](#t3-copd-12-2465){ref-type="table"}). However, when the Asia-Pacific cutoffs were applied, changes in the SGRQ-C and mMRC scores were more constant as the patients fell into the more obese groups. The change in FEV~1~% was more gradual compared to when the WHO cutoffs were applied.

Furthermore, when the WHO classification was applied, the proportion of obese patients was too low (2.5%) to allow a comparison with less obese patients. The proportions of obese patients were 29.6% according to the studies on the distribution of BMI among patients with COPD in both Spain[@b44-copd-12-2465] as well as the Middle East and North Africa.[@b45-copd-12-2465] The study by Rodríguez et al showed that the proportion of the obese was 43% among the selected patients with COPD.[@b46-copd-12-2465] In addition, when evaluating the clinical parameters associated with BMI, such as health-related quality of life, dyspnea score, and respiratory functions, Asia-Pacific classifications can be more appropriate than WHO classifications in Asian patients with COPD.

We assume that the Asia-Pacific BMI classification is more appropriate for Asian patients for the following reasons. A previous study suggested that weight loss in patients with COPD is due to a loss of skeletal muscle volume; on the other hand, a change in fat mass is not a significant contributor.[@b47-copd-12-2465] Furthermore, the fat-free mass index (FFMI) is reported to be more significant than fat mass in the assessment of quality of life and respiratory function of patients with COPD.[@b48-copd-12-2465],[@b49-copd-12-2465] According to the evaluation of Korea National Health and Nutrition Examination Survey (KNHANES), mean BMI and appendicular skeletal muscle (ASM) of Koreans were 24.0±0.0 kg/m^2^ and 22.6±0.1 kg in men and 23.2±0.1 kg/m^2^ and 14.5±0.0 kg in women, respectively.[@b50-copd-12-2465],[@b51-copd-12-2465] In contrast, average BMI and ASM from the US population sample from the National Health and Nutrition Examination Survey (NHANES) were 27.9±0.10 kg/m^2^ and 26.5±0.1 kg in men and 28.2±0.14 in women and 17.8±0.1 kg, respectively.[@b52-copd-12-2465],[@b53-copd-12-2465] Because the Asia-Pacific grading of obesity is based on a consensus that the skeletal and muscle mass of patients in the Asia-Pacific region is lower than that in the West,[@b25-copd-12-2465] we might, therefore, expect a better correlation between BMI according to the Asia-Pacific guidelines than with the WHO grading in Asian patients with COPD.

Metabolic and cardiac problems were more frequent in the obese groups, and such a finding is consistent with the previous study on patients with COPD[@b30-copd-12-2465] and distribution of comorbidities among the general population.[@b54-copd-12-2465],[@b55-copd-12-2465] The prevalence of metabolic disease and cardiovascular disease were much higher when the WHO classification was applied as compared to when the Asia-Pacific classification was applied. The proportion of patients with major comorbidities may differ according to the two different BMI classifications, but the patterns of increase or decrease according to the BMI of the patients with COPD were similar. Moreover, due to the extremely small number of patients falling into the obese category when the WHO cutoffs were applied, some comorbidities such as osteoporosis had an inappropriately high prevalence.

It is widely known that Asian and Western populations differ in mean body mass. However, few studies have compared BMI between Western and Asian patients with COPD. No statistical analysis was conducted for comparison with the other cohorts due to lack of raw data; however, the present study indirectly compared mean BMI of Korean patients with COPD to both Japanese and Western patients with COPD. Interestingly, compared with other major COPD cohorts, the mean BMI of the KOCOSS cohort was much lower than that in the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE; 27±6 kg/m^2^);[@b56-copd-12-2465] such a finding can be explained by the difference in body mass between Western and Asian populations. As expected, the Hokkaido cohort's mean BMI (22±3 kg/m^2^)[@b57-copd-12-2465],[@b58-copd-12-2465] was similar to that for the KOCOSS patients (23±3 kg/m^2^; [Figure 7](#f7-copd-12-2465){ref-type="fig"}).

Our study has a few limitations. First, due to the relatively short duration of the observation period of our recently constructed cohort, the mortality of the study patients could not be evaluated. Second, the body composition data, comprising fat and skeletal muscle mass and quadriceps muscle strength, of patients were not measured. Due to lack of body composition data, evaluation of the association of clinical parameters such as lung function and symptom score to FFMM was limited. We planned to include body composition data for the future study. However, we performed the 6 MWT to evaluate the functional capacity of these patients.

Conclusion
==========

The present study revealed that patients with COPD with a high BMI had better pulmonary function and health-related quality of life and fewer dyspnea symptoms. Furthermore, the results suggest that the Asia-Pacific BMI classification is more appropriate in reflecting the correlation between obesity and the manifestation of COPD in Asian patients compared to that with the WHO classification system. Further studies regarding the clinical significance of BMI classification in Asian patients with COPD are needed.

Supplementary materials
=======================

The names of ethics committees are as follows: Gacheon University Gil Medical Center, Hallym University Kangnam Sacred Heart Hospital, Gangnam Severance Hospital, Kyung Hee University Hospital at Gangdong, Hallym University Kangdong Sacred Heart Hospital, Kangbuk Samsung Hospital, Kangwon National University Hospital, Konkuk University Hospital, Konkuk University Chungju Hospital, Kyungpook National University Hospital, Gyeongsang National University Hospital, Korea University Guro Hospital, Korea University Anam Hospital, Seoul Eulji Hospital, Dongguk University Gyeongju Hospital, Dongguk University Ilsan Hospital, Keimyung University Dongsan Medical Center, Dong-A University Hospital, Hallym University Dongtan Sacred Heart Hospital, Pusan National University Hospital, Inje University Busan Paik Hospital, The Catholic University of Korea Bucheon St Mary's Hospital, Soonchunhyang University Hospital Bucheon, Seoul National University Bundang Hospital, Bundang CHA Hospital, Seoul Metropolitan Government Seoul National University Bora-mae Medical Center, Samsung Medical Center, Soonchunhyang University Hospital Seoul, The Catholic University of Korea Seoul St Mary's Hospital, The Catholic University of Korea St Paul's Hospital, The Catholic University of Korea St Vincent's Hospital, Severance Hospital, Asan Medical Center, Ajou University Hospital, The Catholic University of Korea Yeouido St Mary's Hospital, The Catholic University of Korea Uijeongbu St Mary's Hospital, Yeungnam University Medical Center, Ulsan University Hospital, Wonkwang University Sanbon Hospital, Wonju Severance Christian Hospital, Ewha Womans University Mokding Hospital, Incheon St Mary's Hospital, Inha University Hospital, Chonnam National University Hospital, Chonbuk National University Hospital, Jeju National University Hospital, Soonchunhyang University Hospital Cheonan, Hallym University Chuncheon Sacred Heart Hospital, Hallym University Sacred Heart Hospital, and Hanyang University Guri Hospital.

We also received approval from each center to use their subjects' clinical records for the study while maintaining the confidentiality of the data.

The English in this document has been checked by at least two professional editors, both native speakers of English.

**Disclosure**

The authors report no conflicts of interest in this work.

![Distribution of the body mass index of the study patients.\
**Abbreviation:** BMI, body mass index.](copd-12-2465Fig1){#f1-copd-12-2465}

![Bar graphs showing the distribution of the body mass index of the study patients.\
**Abbreviations:** BMI, body mass index; No, number.](copd-12-2465Fig2){#f2-copd-12-2465}
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###### 

Obesity classification according to WHO and Asia-Pacific guidelines

                WHO (BMI)    Asia-Pacific (BMI)
  ------------- ------------ --------------------
  Underweight   \<18.5       \<18.5
  Normal        18.5--24.9   18.5--22.9
  Overweight    25--29.9     23--24.9
  Obese         ≥30          ≥25

**Abbreviations:** WHO, World Health Organization; BMI, body mass index.

###### 

Baseline characteristics of COPD patients (n=1,462)

  Characteristics          Mean ± SEM or no (%)
  ------------------------ ----------------------
  Male                     1,396 (90.8%)
  Age                      70.5±7.8
  SGRQ-C                   34.6±19.0
  mMRC                     1.5±0.9
  Post-BD FVC (%)          80.5±17.5
  Post-BD FEV~1~ (%)       55.6±18.3
  GOLD 1                   127 (8.7%)
  GOLD 2                   754 (51.9%)
  GOLD 3                   475 (32.7%)
  GOLD 4                   98 (6.7%)
  Post-BD FEV~1~/FVC (%)   48.8±12.3
  BMI (kg/m^2^)            22.8±3.4
  6MWT (m)                 371.4±117.5

**Abbreviations:** SGRQ-C, St George's Respiratory Questionnaire; CAT, COPD assessment test; mMRC, modified Medical Research Council; BD, bronchodilator; GOLD, Global Initiative for Chronic Obstructive Lung Disease; FEV~1~, forced expiratory volume per 1 second; FVC, forced vital capacity; BMI, body mass index; 6MWT, 6-minute walk test.

###### 

Comparison of clinical variables of by BMI categories according to two cutoff systems

                  International classification (WHO)   Asia-Pacific classification                                                                                                            
  --------------- ------------------------------------ ----------------------------- --------------- -------------- --------- --------------- --------------- --------------- --------------- ---------
  Mean age        71.59±8.27                           70.55±7.84                    69.91±7.52      70.57±7.94     0.171     71.59±8.27      70.71±7.82      70.23±7.87      69.98±7.55      0.134
  Male (*n, %*)   144 (90.6)                           857 (92.3)                    294 (87.8)      30 (81.1)      0.014     144 (90.6)      576 (93.7%)     281 (89.8%)     324 (87.1%)     0.006
  SGRQ-C          42.91±21.03                          34.18±18.78                   31.65±17.24     35.59±20.87    \<0.001   42.91±21.03     35.57±19.44     31.42±17.11     32.04±17.63     \<0.001
  mMRC            1.71±1.01                            1.48±0.92                     1.41±0.88       1.65±1.06      0.005     1.71±1.01       1.53±0.93       1.37±0.88       1.43±0.90       0.001
  FEV~1~          46.81±18.09                          55.05±18.03                   60.63±17.72     60.23±14.41    \<0.001   46.81±18.09     53.73±18.06     57.67±17.71     60.59±17.40     \<0.001
  DLCO (%)        64.14±26.48                          74.46±24.73                   82.83±20.70     76.95±17.04    \<0.001   64.14±26.48     72.65±25.73     78.22±22.11     82.29±20.42     \<0.001
  6MWT (m)        331.71±128.52                        373.23±119.02                 384.17±106.81   364.21±97.56   0.001     331.71±128.52   362.22±113.80   393.46±125.80   382.35±106.01   \<0.001

**Abbreviations:** WHO, World Health organization; SGRQ-C, St George's Respiratory Questionnaire; CAT, COPD Assessment Test; mMRC, modified medical research council; FEV~1~, forced expiratory volume per 1 second; FVC, forced vital capacity; DLCO, diffusing capacity of the lung for carbon monoxide.

###### 

Comparison of proportions of airway disease severity in two different body mass classifications

             International classification (WHO)   Asia-Pacific classification                                                                                                                                           
  ---------- ------------------------------------ ----------------------------- ------------- ----------- ------------------------------------------------------ ------------ ------------- ------------- ------------- ------------------------------------------------------
  GOLD I     7 (5.5%)                             78 (61.4%)                    39 (30.7%)    3 (2.4%)    \<0.001[\*](#tfn4-copd-12-2465){ref-type="table-fn"}   7 (5.5%)     43 (33.9%)    35 (27.6%)    42 (33.1%)    \<0.001[\*](#tfn4-copd-12-2465){ref-type="table-fn"}
  GOLD II    49 (6.5%)                            474 (62.9%)                   205 (27.2%)   26 (3.4%)                                                          49 (6.5%)    306 (40.6%)   168 (22.3%)   231 (30.6%)   
  GOLD III   79 (16.6%)                           313 (65.9%)                   76 (16.0%)    7 (1.5%)                                                           79 (16.6%)   216 (45.5%)   97 (20.4%)    83 (17.5%)    
  GOLD IV    21 (21.4%)                           62 (63.3%)                    14 (14.3%)    1 (1.0%)                                                           21 (21.4%)   51 (52.0%)    11 (11.2%)    15 (15.3%)    

**Note:**

*P*-value is for Mantel--Haenszel chi-square test.

**Abbreviation:** GOLD, Global Initiative for Chronic Obstructive Lung Disease.
